Bli medlem
Bli medlem

Du är här

2016-09-01

DBV Technologies: DBV Technologies to Attend Upcoming Investor Conferences

---------------------------------------
| Press Release |
| |
|Montrouge, France, September 1, 2016 |
---------------------------------------

DBV Technologies to Attend Upcoming Investor Conferences

DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market:
DBVT), a clinical-stage specialty biopharmaceutical company, today announced
that members of its management team will present and host investor meetings
at the following investor events in September, 2016:

* Charles Ruban, Chief Commercial Officer, and Susanna Mesa, Senior Vice
President, Strategy, will host investor meetings during Citi's 11thAnnual
Biotech Conference in Boston, MA on Thursday, September 8, 2016.
* Pierre-Henri Benhamou, Chairman&Chief Executive Officer, David Schilansky,
Chief Operating Officer and Susanna Mesa, Senior Vice President, Strategy,
will present at the Morgan Stanley Global Healthcare Conference in New
York, NY on Monday, September 12, 2016, at 2:15 pm ET.
* Susanna Mesa, Senior Vice President, Strategy, will present at the
Rodman&Renshaw 18th Annual Global Investment Conference in New York, NY on
Tuesday, September 13, 2016, at 11:40 am ET.
* Pierre-Henri Benhamou, Chairman&Chief Executive Officer and David
Schilansky, Chief Operating Officer will present at the Bank of America
Merrill Lynch Global Healthcare Conference 2016 in London, UK on Friday,
September 16, 2016, at 1:45 pm BST.

A live webcast of the Morgan Stanley Conference will be available on the
Investor Relations section of the Company's
website:http://www.dbv-technologies.com/en/investor-relations. A replay of
the presentation will also be available on DBV's website within 48 hours
after the event.

About DBV Technologies

DBV Technologies developed Viaskin®, a proprietary technology platform with
broad potential applications in immunotherapy. Viaskin is based on
epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically
active compounds to the immune system through intact skin. With this new
class of self-administered and non-invasive product candidates, the company
is dedicated to safely transforming the care of food allergic patients, for
whom there are no approved treatments. DBV's food allergies programs include
ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical
development of Viaskin Egg. DBV isalso pursuing a human proof concept
clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis,
and exploring potential applications of its platform in vaccines and other
immune diseases.

DBV Technologies has global headquarters in Montrouge, France and New York,
NY. Company shares are traded on segment B of Euronext Paris (Ticker: DBV,
ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq
Global Select Market in the form of American Depositary Shares (each
representing one-half of one ordinary share) (Ticker: DBVT). For more
information on DBV Technologies, please visit our
website:www.dbv-technologies.com

---------------------------------------------------
| DBV Technologies Contact |
| Susanna Mesa |
| |
| |
|Senior Vice President, Strategy |
|+1 212-271-0861 |
|susanna.mesa@dbv-technologies.com |
| Media Contacts |
| Erinn White, Centron PR |
| |
|+1 646-722-8822 |
|ewhite@centronpr.com |
| Media Contacts, Europe |
| |
|Caroline Carmagnol, Alize RP - Relation Presse |
| |
|+33 (0)6 64 18 99 59 |
|caroline@alizerp.com |
| |
---------------------------------------------------
PDF Version
http://hugin.info/156437/R/2038534/759741.pdf

---------------------------------------

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DBV Technologies via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.